Similarity of Insulin Detemir Pharmacokinetics, Safety, and Tolerability Profiles in Healthy Caucasian and Japanese American Subjects
- 8 March 2004
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 44 (3) , 258-264
- https://doi.org/10.1177/0091270003262949
Abstract
The objective of this study was to compare the pharmacokinetics of insulin detemir in three ascending doses in healthy Japanese and Caucasian subjects. This was an open-label, single-center, parallel-group design evaluating 30 subjects (15 Japanese and 15 Caucasians). Subjects received a total of three subcutaneous injections (one injection per visit) of insulin detemir (0.19, 0.38, 0.75 U/kg [1 U = 24 nmol]) in ascending order. Following drug administration, subjects received intravenous glucose in 0.5-mg/kg/min increments every 30 minutes, followed by a constant rate of 2.0 mg/kg/min for up to 12 hours. For pharmacokinetic evaluations, serial blood sampling was performed over a period of 30 hours after dosing. Of the subjects, 36 were enrolled, and 30 completed the study. There was a linear dose-response relationship between the three ascending insulin detemir doses and serum insulin detemir AUC values for both the Japanese and Caucasian subjects. The two dose-response regression lines hod equivalent slopes but slightly different intercepts (although not statistically significant). This difference may be due to variation in AUC, body weight differences, or chance. Six subjects discontinued the study, 2 as a result of adverse events (blood draw-related ecchymosis and hypoglycemia). The most frequent treatment-emergent adverse events (TEAE) were headache, dizziness, and reactions related to blood draws/infusion sites. All TEAEs were mild to moderate in severity. The results show that an increase in insulin detemir dose will result in a similar increase in insulin detemir concentration in the two ethnic groups. Therefore, therapeutic dosing of insulin determir is expected to be similar in both ethnic groups, with no special dose adjustment or algorithm based on race. Insulin detemir at 0.19, 0.38, and 0.75 U/kg was generally well tolerated in both Japanese and Caucasian relationship subjects.Keywords
This publication has 13 references indexed in Scilit:
- Pharmacokinetics of repaglinide in healthy caucasian and Japanese subjects.The Journal of Clinical Pharmacology, 2003
- Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450–metabolized drugsThe American Journal of Medicine, 2002
- Clinical Pharmacokinetics and Pharmacodynamics of Insulin AspartClinical Pharmacokinetics, 2001
- Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humansExperimental and Clinical Endocrinology & Diabetes, 2000
- Populations and genetic polymorphismsMolecular Diagnosis, 1999
- Effect of Fatty Acids and Selected Drugs on the Albumin Binding of a Long-Acting, Acylated Insulin AnalogueJournal of Pharmaceutical Sciences, 1997
- MOLECULAR MECHANISMS OF GENETIC POLYMORPHISMS OF DRUG METABOLISMAnnual Review of Pharmacology and Toxicology, 1997
- World Medical Association Declaration of HelsinkiJAMA, 1997
- Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigsDiabetologia, 1996
- Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivoBiochemical Journal, 1995